1.74
+0.06(+3.57%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.68 |
| Day High | 1.77 |
| Day Low | 1.68 |
| 52-Week High | 4.66 |
| 52-Week Low | 1.63 |
| Volume | 78,967 |
| Average Volume | 308,409 |
| Market Cap | 9.58M |
| PE | -1.04 |
| EPS | -1.68 |
| Moving Average 50 Days | 2.15 |
| Moving Average 200 Days | 2.27 |
| Change | 0.06 |
If you invested $1000 in BioCardia, Inc. (BCDA) 10 years ago, it would be worth $4.11 as of August 13, 2025 at a share price of $1.74. Whereas If you bought $1000 worth of BioCardia, Inc. (BCDA) shares 5 years ago, it would be worth $16.04 as of August 13, 2025 at a share price of $1.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
GlobeNewswire Inc.
Aug 06, 2025 7:18 PM GMT
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate updat
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter
GlobeNewswire Inc.
Aug 04, 2025 10:00 AM GMT
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provides the anticipated timing of reg
BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure
GlobeNewswire Inc.
Jul 24, 2025 1:00 PM GMT
SUNNYVALE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it submitted its CardiAM